Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
Rhea-AI Summary
Calidi Biotherapeutics (NYSE American: CLDI) will host an investor webinar on June 9, 2026, at 1:15pm PT. CEO Eric Poma will review the RedTail targeted virotherapy platform, lead candidate CLD-401, recent preclinical data, 2026 IND plans, upcoming development milestones, and key shareholder catalysts.
Positive
- None.
Negative
- None.
News Market Reaction – CLDI
In the Jun 8 session, CLDI gained 3.55%, reflecting a moderate positive market reaction. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | ASCO abstracts | Positive | +0.8% | ASCO online abstract acceptances for RedTail and lead programs CLD-401, CLD-501. |
| May 22 | Going concern note | Negative | +0.8% | Required NYSE American disclosure of going concern paragraph in 2025 audit report. |
| May 14 | Q1 2026 earnings | Negative | -2.3% | Q1 2026 net loss and cash balance with shifting R&D and G&A expenses. |
| May 13 | Conference presentation | Positive | +8.1% | ASGCT presentation on RedTail platform and preclinical data for CLD-401 and CLD-501. |
| Apr 29 | AI partnership | Positive | -6.9% | Strategic partnership with TransferAI to support CLD-401 IND submission using AI. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock often reacts positively to platform visibility events but has shown mixed moves around financing and partnership news.
Over the last few months, Calidi highlighted its RedTail virotherapy platform and CLD-401 program through conference presentations and ASCO abstract acceptances, with modest positive moves after events like the ASGCT talk on May 13 and ASCO abstracts on May 26. Earnings on May 14 and the TransferAI partnership on April 29 drew negative reactions despite operational progress and an IND target by year-end 2026. The new investor webinar continues this pattern of platform-focused outreach and CLD-401 IND guidance.
Key Terms
virotherapy medical
metastatic medical
il-15 superagonist medical
ind submission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in an investor webinar hosted by RedChip Companies (“RedChip”) on June 9, 2026, at 1:15pm PT.
The exclusive event will feature Eric Poma, Ph.D., Chief Executive Officer of Calidi, who will provide investors with an in-depth overview of Calidi's breakthrough RedTail platform, a next-generation targeted virotherapy designed to deliver genetic medicines systemically to metastatic sites of disease. The discussion will highlight the Company's progress advancing CLD-401, its lead RedTail candidate, toward IND submission by the end of 2026, as well as recent preclinical data demonstrating tumor-selective viral replication, immune evasion capabilities, and localized expression of an IL-15 superagonist payload.
Management will also discuss upcoming development milestones, the broader potential of the RedTail platform across oncology and other disease areas, and key catalysts expected to drive shareholder value creation over the coming year.
A live Q&A session will follow the presentation.
To register for the free webinar, please visit: https://www.redchip.com/webinar/CLDI/89768810764
Questions can be pre-submitted to CLDI@redchip.com or online during the live event.
About Calidi
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
For Media:
